Abametapir carboxyl has a plasma protein binding of 96.0–97.5% and is the predominant of the three substances in the circulation, having a Cmax 30 times and an area under the curve (AUC) 250 times that of abametapir itself.The elimination half-life of abametapir is 21 hours. That of abametapir carboxyl is not well known; it is thought to be 71±40 hours or longer. It is not known whether the drug is eliminated via the urine or the faeces. History
The U.S. Food and Drug Administration (FDA) approved abametapir based on evidence from two identical clinical trials of 699 participants with head lice. The trials were conducted at fourteen sites in the United States.The benefit and side effects of abametapir were evaluated in two clinical trials that enrolled participants with head lice who were at least six months old.About half of all enrolled participants was randomly assigned to abametapir and the other half to placebo. Abametapir lotion or placebo lotion were applied once as a ten-minute treatment to infested hair. The benefit of abametapir in comparison to placebo was assessed after 1, 7 and 14 days by comparing the counts of participants in each group who were free of live lice. References
Further reading
Bowles VM, VanLuvanee LJ, Alsop H, Hazan L, Shepherd K, Sidgiddi S,  et al. (September 2018). "Clinical studies evaluating abametapir lotion, 0.74%, for the treatment of head louse infestation". Pediatr Dermatol. 35 (5): 616–621. doi:10.1111/pde.13612. PMC 6175393. PMID 29999197. External links
"Abametapir". Drug Information Portal. U.S. National Library of Medicine.
Alopecia universalis (AU), also known as alopecia areata universalis, is a medical condition involving the loss of all body hair, including eyebrows, eyelashes, chest hair, armpit hair, and pubic hair. It is the most severe form of alopecia areata. People with the disease are usually healthy and have no other symptoms and a normal life expectancy. Causes
Alopecia universalis can occur at any age, and is currently believed to be an autoimmune disorder, in which a persons immune system attacks the hair follicles. Genetic factors may contribute to AU, as about 20% of those affected have a family member with alopecia. Treatment
Many treatments have been explored, including immunomodulatory agents such as imiquimod. Tofacitinib citrate may also have benefits. In June 2014,  a 25-year-old man with almost no hair on his body was reported to have grown full head of hair, as well as eyebrows, eyelashes, and facial, armpit, and other hair, following eight months of treatment.Contact immunotherapy involves the use of contact allergens, such as diphencyprone  and squaric acid dibutylester, to induce an immune response that is thought to oppose the action of cells causing hair loss. A review that combined and analyzed the findings of 45 studies comprising 2,227 patients showed any hair regrowth in 54.5% and complete hair regrowth in 24.9% of patients with AT and AU using contact immunotherapy.